Lead Toxicity Medication
- Author: Pranay Kathuria, MD; Chief Editor: Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS more...
The mainstay of treatment is chelation therapy. Chelation agents contain sulfhydryl groups that bind or chelate lead, and the resulting complex is excreted either renally or hepatically. The chelation agents succimer and penicillamine are given orally, whereas dimercaprol and edetate (EDTA) calcium disodium (CaNa2 EDTA) are administered parenterally.
These agents reduce body stores of lead. Reducing blood lead levels also may mobilize skeletal stores of lead. Therefore, caution must be exercised in using chelation agents, both because of their adverse effects and because of their ability to mobilize lead.
Antidotes are used to prevent intoxication resulting from lead poisoning. These agents bind lead in the vascular compartment and prevent it from reaching the end organs of toxicity. Chelators promote the excretion of lead.
Succimer, or meso 2,3-dimercaptosuccinic acid (DMSA), is an analogue of dimercaprol used in lead poisoning. It has high sensitivity for lead, but its ability to chelate essential trace metals is low. It is available as capsules of 100 mg. Succimer is generally well tolerated after oral (PO) administration and produces a linear dose-dependent reduction in serum lead concentration. It forms a water-soluble chelate with heavy metals and is excreted in urine. It produces plumburesis approaching that achieved with the combination of CaNa2EDTA and dimercaprol.
In January 1991, succimer became the only drug approved by the US Food and Drug Administration (FDA) specifically for lead chelation in children and the only drug approved to treat a specific laboratory test—namely, a blood lead level (BLL) higher than 45 µg/dL (2.17 mmol/L). It has been shown to be an effective oral chelator.
Although never a substitute for careful environmental controls, succimer produces a rapid decline in lead level and reverses many of the biochemical indicators of toxicity. It is not currently licensed for use in adults. Although experience suggests that this agent is safe and effective, its use must be considered carefully. Adults exposed from an occupational source must be carefully excluded from further exposure.
Patients with extremely high lead levels may experience abnormalities in gastrointestinal (GI) motility; thus, the absorption of succimer may be unpredictable or erratic. Use of this agent in patients with lead levels higher than 60 µg/dL has not been carefully studied. Therefore, consideration should be given to the use of parenteral therapy until lead levels drop below this value.
CaNa2EDTA is nearly the perfect chelator. It is water-soluble, can be administered either intravenously (IV) or intramuscularly (IM), allows lead to be renally eliminated, is not metabolized, and has few toxic effects. Its main limitation is that it removes lead from extracellular spaces only.
CaNa2EDTA should generally be given IV, diluted to a concentration of less than 0.5% in 5% dextrose in water (D5W) or isotonic saline. In patient with acute lead encephalopathy and increased intracranial pressure, dilution to concentration of less than 3.0% may be necessary, or the IM route may be preferred to limit fluids. Ideally, the first dose of dimercaprol should be given at least 4 hours before CaNa2EDTA. Note that CaNa2EDTA initially may aggravate symptoms of lead toxicity because of its mobilization of stored lead.
CaNa2EDTA may induce central nervous system (CNS) toxicity if BAL therapy is not initiated first when blood lead levels are higher than 70 µg/dL in children or 100 µg/dL in adults and in encephalopathy. To prevent hypocalcemia, only CaNa2EDTA should be used for chelation in heavy metal toxicity.
When CaNa2EDTA is given IM, the same daily dose is used, divided into 2-6 doses. IM preparations of CaNa2EDTA are extremely irritating to muscle and intensely painful. Lidocaine or procaine with the IM preparation lessens the pain.
Dimercaprol (British antilewisite [BAL], or 2,3-dimercapto-1-propanol) was the first chelator used in encephalopathic individuals and is the drug of choice for treatment of lead toxicity. It is a chelating agent for intracellular and extracellular lead that and diffuses into red blood cells (RBCs) and rapidly crosses the blood-brain barrier. Sulfhydryl groups combine with ions of heavy metals to form soluble, nontoxic complexes that are excreted renally. Dimercaprol is excreted primarily in bile, making it an agent that can be used in patients with renal failure.
Combination therapy with dimercaprol and CaNa2EDTA is recommended in all cases of severe, acute intoxication (eg, BLL > 100 µg/dL), particularly when encephalopathy is present. Dimercaprol is administered IM every 4 hours, mixed in a peanut oil base; therefore, it should not be used in patients allergic to peanuts. In very severely poisoned patients, the dose is increased to 7 mg/kg, with great caution.
Adverse effects are fever, pain at the injection site, nausea, vomiting, headache, and sterile abscess formation.
D-penicillamine (3-mercapto-D-valine), a second-line oral chelating agent, is a hydrolysis product of penicillin that is FDA-approved for the treatment of Wilson disease and cystinosis. It has been used as an oral chelator of lead for 30 years but has never been licensed for this indication by the FDA.
Penicillamine is effective orally and has few adverse effects. It can be administered over an extended period (weeks to months) for children with lead levels below 45 µg/dL. Penicillamine is available as capsules of 125 mg and 250 mg. Pyridoxine supplementation is required. Adjust the dose for patients with compromised renal function.
Dimercaptopropanesulfonic acid (Dimerval)
Dimercaptopropanesulfonic acid (DPMS) has received much attention worldwide, but it is not yet available in the United States, except under special FDA Investigational New Drug (IND) permits. In Europe and Asia, DPMS has become the drug of choice for most heavy metal intoxications. It is available both in an oral form and in a water-based parenteral form.
Fadrowski JJ, Navas-Acien A, Tellez-Plaza M, Guallar E, Weaver VM, Furth SL. Blood lead level and kidney function in US adolescents: The Third National Health and Nutrition Examination Survey. Arch Intern Med. 2010 Jan 11. 170(1):75-82. [Medline].
Murata K, Iwata T, Dakeishi M, Karita K. Lead toxicity: does the critical level of lead resulting in adverse effects differ between adults and children?. J Occup Health. 2009. 51(1):1-12. [Medline].
Berg R. Lead in adults: the lesser concern rears its head. J Environ Health. 2009 Dec. 72(5):8-13. [Medline].
Canfield RL, Henderson CR Jr, Cory-Slechta DA, Cox C, Jusko TA, Lanphear BP. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med. 2003 Apr 17. 348(16):1517-26. [Medline].
Bellinger DC, Stiles KM, Needleman HL. Low-level lead exposure, intelligence and academic achievement: a long-term follow-up study. Pediatrics. 1992 Dec. 90(6):855-61. [Medline].
Chen A, Dietrich KN, Ware JH, Radcliffe J, Rogan WJ. IQ and blood lead from 2 to 7 years of age: are the effects in older children the residual of high blood lead concentrations in 2-year-olds?. Environ Health Perspect. 2005 May. 113(5):597-601. [Medline]. [Full Text].
Hornung R, Lanphear B, Dietrich K. Response to: "What is the meaning of non-linear dose-response relationships between blood lead concentration and IQ?". Neurotoxicology. 2006 Jul. 27(4):635. [Medline].
Lanphear BP, Hornung R, Khoury J, Yolton K, Baghurst P, Bellinger DC, et al. Low-level environmental lead exposure and children's intellectual function: an international pooled analysis. Environ Health Perspect. 2005 Jul. 113(7):894-9. [Medline]. [Full Text].
Herman SS, Geraldine M, Venkatesh T. Influence of minerals on lead-induced alterations in liver function in rats exposed to long-term lead exposure. J of Hazardous Materials. In press.
Elevated Lead in D.C. Drinking Water - A Study of Potential Causative Events, Final Summary Report. EPA; August 2007:[Full Text].
Onuah, F and Abrak, I. At Least 28 Children Killed by Lead Poisoning in Nigeria. Medscape Medical News. Available at http://www.medscape.com/viewarticle/844746. May 18, 2015; Accessed: September 22, 2015.
Holstege CP, Ferguson JD, Wolf CE, Baer AB, Poklis A. Analysis of moonshine for contaminants. J Toxicol Clin Toxicol. 2004. 42(5):597-601. [Medline].
Cristante AF, de Souza FI, Barros Filho TE, Oliveira RP, Marcon RM. Lead poisoning by intradiscal firearm bullet: a case report. Spine (Phila Pa 1976). 2010 Feb 15. 35(4):E140-3. [Medline].
Norman EH, Bordley WC, Hertz-Picciotto I, Newton DA. Rural-urban blood lead differences in North Carolina children. Pediatrics. 1994 Jul. 94(1):59-64. [Medline].
Jones RL, Homa DM, Meyer PA, Brody DJ, Caldwell KL, Pirkle JL, et al. Trends in blood lead levels and blood lead testing among US children aged 1 to 5 years, 1988-2004. Pediatrics. 2009 Mar. 123(3):e376-85. [Medline].
CDC. US Department of Health and Human Services, National Institute for Occupational Safety and Health; 2013. Adult Blood Lead Epidemiology and Surveillance (ABLES). [Full Text].
Guérin O, Carré N, Garnier R. [Determining factors in lowering blood lead levels below the poisoning threshold in Greater Paris (1992-2006)]. Rev Epidemiol Sante Publique. 2010 Jun. 58(3):181-7. [Medline].
Evans M, Fored CM, Nise G, Bellocco R, Nyrén O, Elinder CG. Occupational lead exposure and severe CKD: a population-based case-control and prospective observational cohort study in Sweden. Am J Kidney Dis. 2010 Mar. 55(3):497-506. [Medline].
Morgan BW, Todd KH, Moore B. Elevated blood lead levels in urban moonshine drinkers. Ann Emerg Med. 2001 Jan. 37(1):51-4. [Medline].
Dietrich KN, Berger OG, Succop PA. Lead exposure and the motor developmental status of urban six-year-old children in the Cincinnati Prospective Study. Pediatrics. 1993 Feb. 91(2):301-7. [Medline].
Fluri F, Balestra G, Christ M, Marsch S, Fuhr P, Rüegg S. Stimulus-induced rhythmic, periodic or ictal discharges (SIRPIDs) elicited by stimulating exclusively the ophthalmic nerve. Clin Neurophysiol. 2008 Aug. 119(8):1934-8. [Medline].
Lead exposure in children: prevention, detection, and management. Pediatrics. 2005 Oct. 116(4):1036-46. [Medline].
American Academy of Pediatrics Committee on Environmental Health. Lead. In:. Handbook of Pediatric Environmental Health. American Academy of Pediatrics. Elk Grove, IL: AAP; 1999:131-43.:
CDC. Preventing Lead Poisoning in Young Children. DC, United States Department of Health and Human Services:1991:[Full Text].
CDC. Screening Young Children for Lead Poisoning. Guidance for State and Local Public Health Officials. . Atlanta, GA: United States Department of Health and Human Services; 1997:[Full Text].
Treatment guidelines for lead exposure in children. American Academy of Pediatrics Committee on Drugs. Pediatrics. 1995 Jul. 96(1 Pt 1):155-60. [Medline].
Carton JA, Maradona JA, Arribas JM. Acute-subacute lead poisoning. Clinical findings and comparative study of diagnostic tests. Arch Intern Med. 1987 Apr. 147(4):697-703. [Medline].
Dietrich KN, Ware JH, Salganik M, Radcliffe J, Rogan WJ, Rhoads GG, et al. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics. 2004 Jul. 114(1):19-26. [Medline].
Atre AL, Shinde PR, Shinde SN, Wadia RS, Nanivadekar AA, Vaid SJ, et al. Pre- and posttreatment MR imaging findings in lead encephalopathy. AJNR Am J Neuroradiol. 2006 Apr. 27(4):902-3. [Medline].
Rogan WJ, Dietrich KN, Ware JH, Dockery DW, Salganik M, Radcliffe J, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med. 2001 May 10. 344(19):1421-6. [Medline].
Thurtle N, Greig J, Cooney L, Amitai Y, Ariti C, Brown MJ, et al. Description of 3,180 courses of chelation with dimercaptosuccinic acid in children ≤ 5 y with severe lead poisoning in Zamfara, Northern Nigeria: a retrospective analysis of programme data. PLoS Med. 2014 Oct. 11 (10):e1001739. [Medline].
Wedeen RP, Malik DK, Batuman V. Detection and treatment of occupational lead nephropathy. Arch Intern Med. 1979 Jan. 139(1):53-7. [Medline].
Lin JL, Ho HH, Yu CC. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial. Ann Intern Med. 1999 Jan 5. 130(1):7-13. [Medline].
Lin JL, Lin-Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med. 2003 Jan 23. 348(4):277-86. [Medline].
Lin JL, Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progressive renal insufficiency. Arch Intern Med. 2001 Jan 22. 161(2):264-71. [Medline].
Mushak P. Lead remediation and changes in human lead exposure: some physiological and biokinetic dimensions. Sci Total Environ. 2003 Feb 15. 303(1-2):35-50. [Medline].
Roberts JR, Reigart JR, Ebeling M, Hulsey TC. Time required for blood lead levels to decline in nonchelated children. J Toxicol Clin Toxicol. 2001. 39(2):153-60. [Medline].
Rust SW, Kumar P, Burgoon DA, Niemuth NA, Schultz BD. Influence of bone-lead stores on the observed effectiveness of lead hazard intervention. Environ Res. 1999 Oct. 81(3):175-84. [Medline].
Centers for Disease Control and Prevention. Adult blood lead epidemiology and surveillance--United States, 2005-2007. MMWR Morb Mortal Wkly Rep. 2009 Apr 17. 58(14):365-9. [Medline].
Flora G, Gupta D, Tiwari A. Toxicity of lead: A review with recent updates. Interdiscip Toxicol. 2012 Jun. 5 (2):47-58. [Medline].